Amid social distancing and other measures to help reduce the spread of coronavirus, digital therapeutics have come into sharper focus. (Image: Shutterstock)
Digital therapeutics are enjoying renewed attention amid the coronavirus crisis, and new industry analyses assert that health benefits managers and advisers might consider these prescription software alternatives as the cost of health care rises.
"Digital therapeutics are poised to change health care by allowing for the diagnosis, management, and treatment of medical conditions in a low-cost, scalable way," the Boston-based tech advisory firm Lux Research said in a new analysis. "All health care stakeholders will be impacted by the adoption of this technology."
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Mike Scarcella
Mike Scarcella is a senior editor in Washington on ALM Media's regulatory desk. Contact him at [email protected]. On Twitter: @MikeScarcella. Mike works on a slate of newsletters: Supreme Court Brief | Higher Law | Compliance Hot Spots | Labor of Law.
